Sonova stock gains as Morgan Stanley raises price target on hearing-aid strength

Published on 09/03/2026 at 09:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sonova stock is benefiting from renewed confidence in the European medtech space, with Morgan Stanley lifting its price target and the Zurich-listed shares trading higher in early September 2026.

Fotorealistische Studioansicht von Over-Ear-Kopfhörer in neutraler Produktdarstellung — Fotorealistische Studioaufnahme von Over-Ear-Kopfhörer zum Thema Sennheiser Momentum 4, ISIN CH0012549785, klare Lichtfuehrung, Illustration mit AI erstellt.

Sonova Holding (ISIN CH0012549785) stock is trading higher at around 238.40 Swiss francs in Zurich as of September 2, 2026, supported by positive sentiment in the Swiss Large & Mid Cap Index and a fresh price-target increase from Morgan Stanley for the hearing-aid specialist. According to market data compiled by Yahoo Finance, the intraday quote of 238.40 Swiss francs reflects a gain of 4.40 Swiss francs or 1.88 percent compared to the previous close on the same date.

Price-target increase highlights hearing-aid momentum

According to an update on European medtech stocks by Morgan Stanley reported on Investing.com dated September 3, 2026, the bank raised its price target for Sonova to 245 Swiss francs from 205 Swiss francs. This represents an increase of roughly 19.5 percent in the target level and signals stronger confidence in the company’s earnings potential over the next 12 to 18 months.

In the same assessment, the analysts describe hearing aids as their preferred subsector within European medtech, expecting market-value growth to return to about 5 percent over the next 12 to 18 months. For Sonova, the new 245 Swiss franc price target now stands slightly above the current market price near 238.40 Swiss francs as of September 2, 2026, outlining upside of almost 3 percent on the latest quote and placing the stock in line with broader sector optimism for hearing-care devices.

Zurich listing and SLI performance support Sonova shares

Sonova shares are listed on SIX Swiss Exchange and form part of the Swiss Large & Mid Cap Index (SLI), giving the stock high visibility among Swiss institutional investors. According to a mid-session overview of the Zurich market from finanzen.ch dated September 2, 2026, Sonova shares traded at 238.00 Swiss francs, marking a gain of 1.71 percent within the SLI at midday and ranking among the stronger performers alongside large-cap peers such as Roche and Swisscom.

Later the same day, a closing report on the SLI from finanzen.net shows Sonova at 237.20 Swiss francs, up 1.37 percent compared with the prior day, again among the strongest individual values in the index. The report also notes a euro-converted indication of 246.90 for Sonova, underlining the stock’s relevance for investors following the Swiss hearing-aid group through German-language trading portals.

Go deeper

More Sonova stock and background data

For additional Sonova stock coverage and regulatory news, the following overview offers a starting point for further research.

Sonova news and price overview Investor Relations

Product focus: rechargeable in-ear hearing aids

Beyond the stock-market reaction, Sonova is also shaping the hearing-aid market with new products in the premium segment. According to a product overview on in-ear hearing aids from electronics.alibaba.com dated August 2026, Sonova introduced Phonak’s smallest and first rechargeable in-the-ear hearing aid to its Infinio line, targeting users looking for discreet devices that integrate seamlessly into daily life.

The same source describes the in-ear hearing-aid market as expanding at a compound annual growth rate of about 6 percent, driven by aging populations and rising acceptance of advanced hearing solutions. For Sonova, strong positioning in rechargeable and Bluetooth-enabled hearing aids complements its traditional audiology channel and supports the medium-term growth narrative that underpins analyst optimism and the recent upward revision of the price target to 245 Swiss francs.

Sonova stock level and investor takeaway

As of September 2, 2026, Sonova stock trades around 238.40 Swiss francs on SIX Swiss Exchange, close to the newly raised 245 Swiss franc price target by Morgan Stanley and supported by solid performance within the Swiss Large & Mid Cap Index. For investors, the key points now are the bank’s expectation of roughly 5 percent market-value growth in hearing aids over the next 12 to 18 months and Sonova’s role as a leading supplier of advanced rechargeable in-ear devices, which together frame the current risk-reward profile of the shares.